117 related articles for article (PubMed ID: 37860893)
41. Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy.
Miller RE; Markt SC; O'Donnell E; Bernard B; Albiges LK; Beard C; Sweeney CJ
Eur Urol Focus; 2017 Dec; 3(6):621-628. PubMed ID: 28753801
[TBL] [Abstract][Full Text] [Related]
42. Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease.
Abdul Razak AR; Li L; Bryant A; Diaz-Padilla I
Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD007584. PubMed ID: 21412906
[TBL] [Abstract][Full Text] [Related]
43. Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus.
Rolevich AI; Borodin DM; Rabcheuski AN; Ivanitskaya TA; Semenov SA; Artsiushkevich LV; Sukalinskaya AV; Zhavrid EA; Krasny SA; Konoplya NE; Polyakov SL
JCO Glob Oncol; 2021 Jan; 7():63-71. PubMed ID: 33434070
[TBL] [Abstract][Full Text] [Related]
44. Descriptive epidemiology of germ cell tumors of the central nervous system diagnosed in the United States from 2006 to 2015.
Gittleman H; Cioffi G; Vecchione-Koval T; Ostrom QT; Kruchko C; Osorio DS; Finlay JL; Barnholtz-Sloan JS
J Neurooncol; 2019 Jun; 143(2):251-260. PubMed ID: 31025275
[TBL] [Abstract][Full Text] [Related]
45. Incidence and survival of children and young people with central nervous system embryonal tumours in the North of England, 1990-2013.
Fairley L; Picton SV; McNally RJ; Bailey S; McCabe MG; Feltbower RG
Eur J Cancer; 2016 Jul; 61():36-43. PubMed ID: 27151553
[TBL] [Abstract][Full Text] [Related]
46. Treatment and survival patterns for germ cell tumors among 13- to 24-year olds in Yorkshire, UK.
Feltbower RG; Siller C; Woodward E; McKinney PA; Picton SV; Joffe J; Stark DP
Pediatr Blood Cancer; 2011 Feb; 56(2):282-8. PubMed ID: 21157895
[TBL] [Abstract][Full Text] [Related]
47. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
[TBL] [Abstract][Full Text] [Related]
48. The prognostic value of DNA damage level in peripheral blood lymphocytes of chemotherapy-naïve patients with germ cell cancer.
Sestakova Z; Kalavska K; Hurbanova L; Jurkovicova D; Gursky J; Chovanec M; Svetlovska D; Miskovska V; Obertova J; Palacka P; Rejlekova K; Sycova-Mila Z; Cingelova S; Spanik S; Mardiak J; Chovanec M; Mego M
Oncotarget; 2016 Nov; 7(46):75996-76005. PubMed ID: 27732956
[TBL] [Abstract][Full Text] [Related]
49. Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages.
Kliesch S; Schmidt S; Wilborn D; Aigner C; Albrecht W; Bedke J; Beintker M; Beyersdorff D; Bokemeyer C; Busch J; Classen J; de Wit M; Dieckmann KP; Diemer T; Dieing A; Gockel M; Göckel-Beining B; Hakenberg OW; Heidenreich A; Heinzelbecker J; Herkommer K; Hermanns T; Kaufmann S; Kornmann M; Kotzerke J; Krege S; Kristiansen G; Lorch A; Müller AC; Oechsle K; Ohloff T; Oing C; Otto U; Pfister D; Pichler R; Recken H; Rick O; Rudolph Y; Ruf C; Schirren J; Schmelz H; Schmidberger H; Schrader M; Schweyer S; Seeling S; Souchon R; Winter C; Wittekind C; Zengerling F; Zermann DH; Zillmann R; Albers P
Urol Int; 2021; 105(3-4):169-180. PubMed ID: 33412555
[TBL] [Abstract][Full Text] [Related]
50. Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy.
Ko JJ; Bernard B; Tran B; Li H; Asif T; Stukalin I; Lee M; Day D; Alimohamed N; Sweeney CJ; Bedard PL; Heng DY
J Clin Oncol; 2016 Mar; 34(7):714-20. PubMed ID: 26786931
[TBL] [Abstract][Full Text] [Related]
51. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.
Raggi D; Mariani L; Giannatempo P; Lo Vullo S; Giardiello D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Calareso G; Magni M; Di Nicola M; Verzoni E; Grassi P; Procopio G; De Braud F; Pizzocaro G; Salvioni R; Necchi A
Urol Oncol; 2015 Jul; 33(7):332.e19-24. PubMed ID: 25985712
[TBL] [Abstract][Full Text] [Related]
52. Small Numbers, Big Challenges: Adolescent and Young Adult Cancer Incidence and Survival in New Zealand.
Ballantine KR; Watson H; Macfarlane S; Winstanley M; Corbett RP; Spearing R; Stevanovic V; Yi M; Sullivan MJ
J Adolesc Young Adult Oncol; 2017 Jun; 6(2):277-285. PubMed ID: 28207291
[TBL] [Abstract][Full Text] [Related]
53. Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors.
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Bokemeyer C
Eur J Cancer; 2018 May; 94():16-25. PubMed ID: 29505967
[TBL] [Abstract][Full Text] [Related]
54. Central nervous system germ cell tumor, an archetypal AYA tumor and a model for pediatric and neuro-oncology collaboration, review from the EURACAN domain 10 group.
Faure Conter C; Calaminus G; Nicholson J; Idbaih A; Hoang Xuan K; Vasiljevic A; Morana G; Szathmari A; Ajithkumar T; Frappaz D
Front Oncol; 2022; 12():971697. PubMed ID: 36248981
[No Abstract] [Full Text] [Related]
55. [SENTIERI - Epidemiological Study of Residents in National Priority Contaminated Sites. Sixth Report].
Zona A; Fazzo L; Benedetti M; Bruno C; Vecchi S; Pasetto R; Minichilli F; De Santis M; Nannavecchia AM; Di Fonzo D; Contiero P; Ricci P; Bisceglia L; Manno V; Minelli G; Santoro M; Gorini F; Ancona C; Scondotto S; Soggiu ME; Scaini F; Beccaloni E; Marsili D; Villa MF; Maifredi G; Magoni M; Iavarone I;
Epidemiol Prev; 2023; 47(1-2 Suppl 1):1-286. PubMed ID: 36825373
[TBL] [Abstract][Full Text] [Related]
56. Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older.
Feldman DR; Voss MH; Jacobsen EP; Jia X; Suarez JA; Turkula S; Sheinfeld J; Bosl GJ; Motzer RJ; Patil S
Cancer; 2013 Jul; 119(14):2574-81. PubMed ID: 23606402
[TBL] [Abstract][Full Text] [Related]
57. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
58. Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference.
Nicolai N; Biasoni D; Catanzaro MA; Colecchia M; Trama A;
Eur J Surg Oncol; 2019 Jan; 45(1):60-66. PubMed ID: 29526370
[TBL] [Abstract][Full Text] [Related]
59. Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration.
Giannatempo P; Pond GR; Sonpavde G; Albany C; Loriot Y; Sweeney CJ; Salvioni R; Colecchia M; Nicolai N; Raggi D; Rice KR; Flack CK; El Mouallem NR; Feldman H; Fizazi K; Einhorn LH; Foster RS; Necchi A; Cary C
J Urol; 2016 Jul; 196(1):95-100. PubMed ID: 26748165
[TBL] [Abstract][Full Text] [Related]
60. Cancer Among Adolescents and Young Adults Between 2000 and 2016 in France: Incidence and Improved Survival.
Raze T; Lacour B; Cowppli-Bony A; Delafosse P; Velten M; Trétarre B; Defossez G; Hammas K; Woronoff AS; Ganry O; Plouvier S; Coureau G; Guizard AV; Bara S; Monnereau A; Daubisse-Marliac L; Troussard X; D'Almeida T; Baldi I; Bouvier V; Boissel N; Clavel J; Desandes E
J Adolesc Young Adult Oncol; 2021 Feb; 10(1):29-45. PubMed ID: 32412825
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
